Tissue factor and factor VIIa cross-species compatibility.

Front Biosci (Landmark Ed)

Haemostasis Pharmacology, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Malov, Denmark.

Published: June 2011

Knowledge about species compatibility is crucial for proper interpretation of data from in vivo experiments with human proteins in pharmacological models and of data from cross-species in vitro experiments. Information about the cross-species compatibility of tissue factor (TF) and coagulation factor (F) VII (FVII) has accumulated since the early history of coagulation research. Many observations were connected to the introduction and development of the prothrombin time (PT) assay where fibrin clot formation was observed when tissue extracts of different origins were added to recalcified human or non-human plasmas. Studies on cross-species TF-FVIIa compatibility entered into a new area with the cloning and recombinant expression of TF and FVII from a number of species as well as with the possibility of specific amino acid substitution. TF and/or FVIIa from cattle, dog, rabbit, mouse, rat and zebrafish have been purified and characterized in varying detail. In addition to adding knowledge about the species-specific TF-FVIIa interactions, cross-species studies often reveal information which adds to the general view of the structural and functional properties of the human TF-FVIIa complex. This review briefly outlines the features of human TF and FVIIa, their intermolecular interactions, and the biological effects of TF-FVIIa complex formation and compares this information to findings obtained in studies addressing TF or FVIIa of non-human origin. By examples we point to difficulties which may arise from the transcendence across species borders and how some cross-species data have advanced our understanding of the structure and function of the human TF-FVIIa complex.

Download full-text PDF

Source
http://dx.doi.org/10.2741/3906DOI Listing

Publication Analysis

Top Keywords

tf-fviia complex
12
tissue factor
8
cross-species compatibility
8
human tf-fviia
8
cross-species
6
human
5
tf-fviia
5
factor factor
4
factor viia
4
viia cross-species
4

Similar Publications

Formation of the extrinsic complex (EC) on cell surfaces is the event that triggers the coagulation cascade. Tissue factor (TF) and factor VIIa (FVIIa) form the EC together with factor X (FX) on phosphatidylserine-containing membranes, leading to FX activation by TF:FVIIa. This lipid dependence has made experimental characterization of the EC structure challenging.

View Article and Find Full Text PDF

Tissue factor (TF) and protease-activated receptor 2 (PAR2) have been associated with the progression of cancer, while integrins are essential for the adhesion and migration of cancer cells. This study aimed to explore the cross-talk between the TF:FVIIa complex, PAR2 signaling, and the expression of integrin α1 in cervical cancer cells. Utilizing data from The Cancer Genome Atlas (TCGA), the research examined the relationship between the TF and PAR2 genes and the integrin α1 gene (ITGA1) in reproductive cancers, revealing a positive correlation between integrin α1 expression and both TF and PAR2 genes.

View Article and Find Full Text PDF
Article Synopsis
  • - Neutrophils can release their DNA and contents to fight infections, but this can impact blood coagulation through a protein called TFPI, which is affected by an enzyme (PAD4) that alters (citrullinates) it, reducing its ability to prevent blood clotting.
  • - The study aimed to explore how this citrullination affects TFPI's performance in inhibiting key components of blood coagulation, specifically FXa and the FVIIa/tissue factor complex, using various laboratory techniques.
  • - Results showed that while citrullination severely weakened TFPI's ability to inhibit FXa, it still had some effect on FVIIa/tissue factor activity with the help of another protein (
View Article and Find Full Text PDF

Examining downstream effects of concizumab in hemophilia A with a mathematical modeling approach.

J Thromb Haemost

November 2024

Department of Mathematics, University of North Carolina at Chapel Hill, Chapel Hill, NC; Computational Medicine Program, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. Electronic address:

Background: Tissue factor (TF) pathway inhibitor (TFPI) is an anticoagulant protein that inhibits factor (F)Xa, the TF-FVIIa-FXa complex, and early forms of the prothrombinase complex. Concizumab is a monoclonal antibody that blocks FXa inhibition by TFPI and reduces bleeding in hemophilia.

Objectives: To examine how concizumab impacts various reactions of TFPI to restore thrombin generation in hemophilia A using mathematical models.

View Article and Find Full Text PDF

Back to basics: the coagulation pathway.

Blood Res

October 2024

Daisy Hill Hospital, 5 Hospital Road, Newry, BT35 8DR, UK.

The classic coagulation cascade model of intrinsic and extrinsic coagulation pathways, i.e. contact activation pathway and tissue factor pathway, has been widely modified.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!